{
    "pmcid": "8590000",
    "qa_pairs": {
        "What computational tool was used to redesign the complementarity-determining regions (CDRs) of Fab CC12.3 to enhance its binding affinity to SARS-CoV-2-RBD?": [
            "RosettaAntibodyDesign (RAbD)",
            "PyMOL",
            "AutoDock Vina",
            "GROMACS"
        ],
        "What specific interactions were highlighted as important for enhancing the binding affinity of the redesigned Fabs?": [
            "Electrostatic interactions, van der Waals forces, and non-polar solvation",
            "Hydrogen bonding, pi-stacking, and covalent bonding",
            "Ionic interactions, hydrophobic effects, and disulfide bridges",
            "Metal coordination, salt bridges, and peptide bond formation"
        ],
        "What was the binding free energy threshold used to select sequences for further validation in the study?": [
            "-40.0 Rosetta Energy Units (REU)",
            "-30.0 Rosetta Energy Units (REU)",
            "-50.0 Rosetta Energy Units (REU)",
            "-20.0 Rosetta Energy Units (REU)"
        ],
        "Which method was employed to calculate the binding free energies during the validation of redesigned Fabs through molecular dynamics simulations?": [
            "MM-GBSA",
            "FEP+",
            "LIE",
            "SASA"
        ],
        "Which redesigned Fab showed the most promise as a potential therapeutic candidate due to its superior binding affinity compared to ACE2?": [
            "CC12.3-D08",
            "CC12.3-D01",
            "CC12.3-D04",
            "CC12.3-D07"
        ]
    }
}